| P50 | author | Richard K Plemper | Q89312727 |
| | Michael G. Natchus | Q114519255 |
| P2093 | author name string | Jeong-Joong Yoon | |
| | Michael Hart | |
| | George R Painter | |
| | Mart Toots | |
| P2860 | cites work | Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. | Q55426854 |
| | Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses | Q57095720 |
| | Treating Influenza Infection, From Now and Into the Future | Q57158941 |
| | Neuraminidase inhibitor resistance in influenza: a clinical perspective | Q57296842 |
| | In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit | Q57474158 |
| | The mechanism of resistance to favipiravir in influenza | Q57799444 |
| | Animal models used to assess influenza antivirals | Q58542481 |
| | Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents | Q59353237 |
| | Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons | Q61814222 |
| | High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza | Q73570981 |
| | Modelling of optimal timing for influenza vaccination as a function of intraseasonal waning of immunity and vaccine coverage | Q90108074 |
| | Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia | Q90910407 |
| | Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains | Q92661086 |
| | Neuraminidase inhibitors for preventing and treating influenza in adults and children | Q24197463 |
| | A simple practice guide for dose conversion between animals and human | Q26750843 |
| | Modeling human influenza infection in the laboratory | Q26781842 |
| | Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness | Q27000668 |
| | Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets | Q27312721 |
| | Influenza vaccination accelerates recovery of ferrets from lymphopenia | Q27321447 |
| | Peripheral Leukocyte Migration in Ferrets in Response to Infection with Seasonal Influenza Virus | Q27336918 |
| | Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening | Q28830304 |
| | A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans | Q30233717 |
| | Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. | Q30361125 |
| | Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. | Q30362700 |
| | How high is a high risk? Prioritising high-risk individuals in an influenza pandemic. | Q30369221 |
| | Favipiravir: a new medication for the Ebola virus disease pandemic. | Q30370190 |
| | Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection | Q30387267 |
| | Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets | Q30403382 |
| | Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis | Q30408691 |
| | Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients | Q30424329 |
| | T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro | Q30426020 |
| | The impact of medication regimen factors on adherence to chronic treatment: a review of literature | Q30436145 |
| | Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations | Q33804210 |
| | Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. | Q34217769 |
| | Clinical profiles associated with influenza disease in the ferret model | Q34614939 |
| | Animal Models for Influenza Virus Pathogenesis and Transmission | Q34714853 |
| | Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials | Q35097867 |
| | Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung | Q37087961 |
| | Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies | Q38803189 |
| | Distinct pathogenesis of hong kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses | Q39588325 |
| | High prevalence of amantadine resistance among circulating European porcine influenza A viruses | Q39882839 |
| | Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa | Q39973215 |
| | Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States | Q45118572 |
| | Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness | Q49989801 |
| | Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine. | Q55339400 |
| P304 | page(s) | 16-28 | |
| P577 | publication date | 2019-12-25 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model | |
| P478 | volume | 218 | |